Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance.
Hashemi M, Hajimazdarany S, Mohan CD, Mohammadi M, Rezaei S, Olyaee Y, Goldoost Y, Ghorbani A, Mirmazloomi SR, Gholinia N, Kakavand A, Salimimoghadam S, Ertas YN, Rangappa KS, Taheriazam A, Entezari M. Hashemi M, et al. Among authors: rezaei s. Pharmacol Res. 2022 Dec;186:106535. doi: 10.1016/j.phrs.2022.106535. Epub 2022 Nov 2. Pharmacol Res. 2022. PMID: 36334877 Review.
STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response.
Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. Sadrkhanloo M, et al. Among authors: rezaei s. Pharmacol Res. 2022 Aug;182:106311. doi: 10.1016/j.phrs.2022.106311. Epub 2022 Jun 15. Pharmacol Res. 2022. PMID: 35716914 Review.
LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions.
Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, Daneshi S, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. Entezari M, et al. Among authors: rezaei s. Biomed Pharmacother. 2022 Oct;154:113609. doi: 10.1016/j.biopha.2022.113609. Epub 2022 Aug 27. Biomed Pharmacother. 2022. PMID: 36037786 Free article. Review.
SOX2 function in cancers: Association with growth, invasion, stemness and therapy response.
Mirzaei S, Paskeh MDA, Entezari M, Mirmazloomi SR, Hassanpoor A, Aboutalebi M, Rezaei S, Hejazi ES, Kakavand A, Heidari H, Salimimoghadam S, Taheriazam A, Hashemi M, Samarghandian S. Mirzaei S, et al. Among authors: rezaei s. Biomed Pharmacother. 2022 Dec;156:113860. doi: 10.1016/j.biopha.2022.113860. Epub 2022 Oct 20. Biomed Pharmacother. 2022. PMID: 36272267 Free article. Review.
Targeting PI3K/Akt signaling in prostate cancer therapy.
Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, Salimimoghadam S, Mirzaei S, Entezari M, Samarghandian S. Hashemi M, et al. Among authors: rezaei s. J Cell Commun Signal. 2023 Sep;17(3):423-443. doi: 10.1007/s12079-022-00702-1. Epub 2022 Nov 11. J Cell Commun Signal. 2023. PMID: 36367667 Free PMC article. Review.
siRNA and targeted delivery systems in breast cancer therapy.
Mirzaei S, Paskeh MDA, Entezari M, Bidooki SH, Ghaleh VJ, Rezaei S, Hejazi ES, Kakavand A, Behroozaghdam M, Movafagh A, Taheriazam A, Hashemi M, Samarghandian S. Mirzaei S, et al. Among authors: rezaei s. Clin Transl Oncol. 2023 May;25(5):1167-1188. doi: 10.1007/s12094-022-03043-y. Epub 2022 Dec 23. Clin Transl Oncol. 2023. PMID: 36562927 Review.
The pharmacological and biological importance of EZH2 signaling in lung cancer.
Entezari M, Taheriazam A, Paskeh MDA, Sabouni E, Zandieh MA, Aboutalebi M, Kakavand A, Rezaei S, Hejazi ES, Saebfar H, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. Entezari M, et al. Among authors: rezaei s. Biomed Pharmacother. 2023 Apr;160:114313. doi: 10.1016/j.biopha.2023.114313. Epub 2023 Feb 3. Biomed Pharmacother. 2023. PMID: 36738498 Free article. Review.
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.
Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Hashemi M, et al. Among authors: rezaei s. Biomed Pharmacother. 2023 Apr;160:114392. doi: 10.1016/j.biopha.2023.114392. Epub 2023 Feb 15. Biomed Pharmacother. 2023. PMID: 36804123 Free article. Review.
Wnt/β-catenin Signaling in Lung Cancer: Association with Proliferation, Metastasis, and Therapy Resistance.
Entezari M, Deldar Abad Paskeh M, Orouei S, Kakavand A, Rezaei S, Sadat Hejazi E, Pashootan P, Nazdari N, Tavakolpournegari A, Hashemi M, Salimimoghadam S, Mirzaei S, Taheriazam A, Samarghandian S. Entezari M, et al. Among authors: rezaei s. Curr Cancer Drug Targets. 2023 Apr 13. doi: 10.2174/1568009623666230413094317. Online ahead of print. Curr Cancer Drug Targets. 2023. PMID: 37069720
miRNAs as short non-coding RNAs in regulating doxorubicin resistance.
Mirzaei S, Paskeh MDA, Moghadam FA, Entezari M, Koohpar ZK, Hejazi ES, Rezaei S, Kakavand A, Aboutalebi M, Zandieh MA, Rajabi R, Salimimoghadam S, Taheriazam A, Hashemi M, Samarghandian S. Mirzaei S, et al. Among authors: rezaei s. J Cell Commun Signal. 2023 Dec;17(4):1181-1202. doi: 10.1007/s12079-023-00789-0. Epub 2023 Nov 29. J Cell Commun Signal. 2023. PMID: 38019354 Free PMC article. Review.
617 results